To construct a treatment option with Viramune (nevirapine) and antiretroviral, e.g. Combivir (fixed dose combination of Zidovudine and Lamivudine), Kivexa (fixed dose combination of Abacavir and Lamivudine) or Truvada (fixed dose combination of tenofovir and emtricitabine) in male and female adult HIV type 1 infected patients, who have either not been treated previously, whose previous combination treatment with protease inhibitors has failed, or who have to switch their previous treatment from protease inhibitor or nucleosidaI reverse transcriptase inhibitor due to side effects or intolerability after achieving suppression of viral load below the limit of detection. Viramune (nevirapine) is indicated as part of combination therapy for the antiviral treatment of HIV-1 infected patients with advanced or progressive immunodeficiency.
pAge < 18 years Pregnant female patients Hypersensitivity to the active substance or to any of the excipients of Viramune (nevirapine) or antiretroviral in combination with Viramune, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir and emtricitabine).
Viramune (nevirapine) should not be readministered to patients who have required permanent discontinuation for severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine.
Viramune (nevirapine) should not be used in patients with severe hepatic impairment (Child-Pugh C) or pre-treatment GOT (Glutamic Oxaloacetic Transaminase) or GPT (Glutamic Pyruvate Transaminase) > 5 upper limit of normal until baseline GOT/GPT are stabilised < 5 upper limit of normal.
Viramune (nevirapine) should not be readministered in patients who previously had GOT or GPT (Liver enzymes) > 5 ULN (upper limit of normal) during Viramune (nevirapine) therapy and had recurrence of liver function abnormalities upon readministration of Viramune (nevirapine) Herbal preparations containing St Johns wort (Hypericum perforatum) must not be used while taking Viramune (nevirapine) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine The available pharmacokinetic data suggest that the concomitant use of rifampicin and Viramune (nevirapine) is not recommended.